- Home
- NVO
NVO
Novo Nordisk A/S
as 11-05-2025 4:00pm EST
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 243.4B | IPO Year: | N/A |
| Target Price: | $80.40 | AVG Volume (30 days): | 13.5M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.67 | EPS Growth: | 10.06 |
| 52 Week Low/High: | $45.05 - $112.52 | Next Earning Date: | 11-05-2025 |
| Revenue: | $49,580,393,058 | Revenue Growth: | 16.64% |
| Revenue Growth (this year): | 9.21% | Revenue Growth (next year): | 5.64% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Yahoo Finance Video
21 hours ago
Novo Nordisk cuts outlook, IBM layoffs, Pinterest stock plummets
MT Newswires
21 hours ago
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday
The Wall Street Journal
21 hours ago
Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs
Investor's Business Daily
a day ago
Novo Nordisk Skids After Cutting Its Outlook For The Third Time This Year
Yahoo Finance
a day ago
Earnings live: AMD, Supermicro, and Novo Nordisk stocks fall, Pinterest tanks while Lemonade gets a boost
Yahoo Finance Video
a day ago
McDonalds and Novo Nordisk report earnings
PR Newswire
a day ago
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
Barrons.com
a day ago
Novo Nordisk Stock Falls After Earnings. It Cut Guidance on These Fears.
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.